Key Takeaway: Cognition Therapeutics is promoting awareness for Lewy Body Dementia during the designated awareness month. This initiative aims to educate the public about the condition and its impact on patients and families. The company emphasizes the significance of understanding Lewy Body Dementia to foster better support and resources.
Price reaction · baseline $0.4686 (2024-09-30 close) · hit pre-market · 1 other CGTX headline(s) in the window, move may be shared
day 0 close
-6.1%
day 1
-3.8%
day 3 · peak
-7.2%
Market Sentiment Analysis
POSITIVE FACTORS
Cognition Therapeutics is actively supporting Lewy Body Dementia awareness.
The initiative highlights the importance of raising awareness for this condition.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Frequently Asked Questions
What is Cognition Therapeutics doing for Lewy Body Dementia?
Cognition Therapeutics is promoting awareness for Lewy Body Dementia this month.
Why is Lewy Body Dementia awareness important?
Raising awareness helps educate the public about the condition and its impact.